| NCT06099951 | Sun Yat-sen University | Colorectal Cancer | 2023-11-01 | PHASE2 |
| NCT05769725 | RenJi Hospital | Serplulimab,Gastric Cancer, Adjuvant Therapy | 2023-03-01 | PHASE2 |
| NCT05957510 | Guangdong Association of Clinical Trials|Guangdong Provincial People´s Hospital | Small-cell Lung Cancer | 2023-07-07 | PHASE2 |
| NCT07527520 | Fudan University | Rectal Cancer|Moderately Hypofractionated Radiotherapy|Serplulimab|pMMR+MSS | 2026-06 | PHASE2 |
| NCT07269782 | Shanghai Henlius Biotech | Non Small Cell Lung Cancer | 2026-01-20 | PHASE2 |
| NCT06461910 | Zekuan Xu | Gastric Cancer|Esophagogastric Junction Adenocarcinoma | 2024-06-14 | PHASE2 |
| NCT06393166 | Zhejiang Cancer Hospital | Non-Resectable Pancreas Carcinoma | 2023-05-01 | PHASE2 |
| NCT06433869 | Sun Yat-sen University | Malignant Ascites | 2023-12-14 | PHASE2 |
| NCT07141771 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | SCLC, Extensive Stage | 2025-12-31 | PHASE1|PHASE2 |
| NCT05468489 | Shanghai Henlius Biotech | Extensive Stage Small Cell Lung Cancer | 2022-11-18 | PHASE3 |
| NCT06716619 | Guangzhou FineImmune Biotechnology Co., LTD.|Sun Yat-sen University | Tumor Associated Lymph Node T Cell|Advanced Solid Tumor|Immunotherapy|Serplulimab Injection | 2025-02-13 | PHASE1 |
| NCT05585580 | Qilu Hospital of Shandong University | Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | 2023-03-01 | PHASE2 |
| NCT06368141 | Ruijin Hospital | Colon Cancer | 2024-05-01 | PHASE2 |
| NCT07277842 | Sun Yat-sen University | Locally Advanced Low Rectal Adenocarcinoma|pMMR (Microsatellite Stable Rectal Cancer) | 2025-12-29 | PHASE3 |
| NCT06128252 | Tang-Du Hospital | Gastric Cancer | 2024-09-01 | NA |
| NCT07418866 | Fudan University | NSCLC (Advanced Non-small Cell Lung Cancer) | 2026-02 | PHASE2 |
| NCT06280495 | Sun Yat-sen University | Colorectal Cancer|Liver Metastases | 2024-02-01 | PHASE2|PHASE3 |
| NCT06781281 | Henan Cancer Hospital | Breast Cancer Invasive | 2024-12-04 | |
| NCT06491355 | Sir Run Run Shaw Hospital | Efficacy, Self|Safety Issues|Colo-rectal Cancer | 2024-07-01 | PHASE2 |
| NCT05954429 | Fudan University | Colorectal Cancer | 2023-07-20 | PHASE2 |
| NCT05731726 | Zhejiang University | pMMR|MSS|MSI-L|Locally Advanced Rectal Carcinoma | 2023-02-22 | PHASE2 |
| NCT07381400 | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Rectal Cancer | 2026-02-01 | PHASE2 |
| NCT05975749 | Fudan University | Gastric Cancer | 2023-01-01 | PHASE2 |
| NCT07488533 | Sun Yat-sen University | Non-Clear Cell Renal Cell Carcinoma | 2025-08-01 | PHASE2 |
| NCT05747729 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Neuroendocrine Carcinoma | 2023-02-28 | PHASE1|PHASE2 |
| NCT06295926 | Peking Union Medical College Hospital | Small Cell Lung Cancer | 2024-04-04 | PHASE2 |
| NCT07235930 | Zhejiang Cancer Hospital | Non-Resectable Pancreas Carcinoma | 2025-11-15 | PHASE3 |
| NCT06335147 | Henan Cancer Hospital | Metastatic Colon Cancer | 2024-04-01 | NA |
| NCT07358585 | Shanghai Henlius Biotech | Colon Cancer Adenocarcinoma | 2026-01-31 | PHASE1|PHASE2 |
| NCT06727617 | Tianjin Medical University Cancer Institute and Hospital | Cervical Cancers | 2024-11-19 | PHASE2 |
| NCT05501340 | Second Affiliated Hospital of Soochow University | Malignant Ascites | 2022-09-01 | PHASE1|PHASE2 |
| NCT07318883 | Shanghai Henlius Biotech | Squamous NSCLC | 2026-03 | PHASE2|PHASE3 |
| NCT05807893 | Sun Yat-sen University | Non-small Cell Lung Cancer Stage II|Bevacizumab|Immunotherapy|Brain Metastases | 2023-05-14 | PHASE2|PHASE3 |
| NCT05787613 | Shanghai Henlius Biotech | NSCLC Stage IV | 2023-07-10 | PHASE2 |
| NCT05675033 | Fujian Cancer Hospital | Lung Adenocarcinoma|Stage IV Non-small Cell Lung Cancer|PD-1 Inhibitor|VEGF | 2023-01-10 | PHASE2 |
| NCT06354218 | The First Affiliated Hospital with Nanjing Medical University | Esophageal Carcinoma | 2023-12-01 | PHASE2 |
| NCT07175389 | West China Hospital | Refractory Pancreatic Ductal Adenocarcinoma|Refractory Pancreatic Adenocarcinoma | 2025-10-01 | PHASE1|PHASE2 |
| NCT05742425 | Second Affiliated Hospital, School of Medicine, Zhejiang University|Changxing People´s Hospital | Unresectable Colon Cancer Peritoneal Metastases|PMMR+Ras+BRAF Wild-type | 2023-03 | PHASE2 |
| NCT06911606 | Guangdong Provincial People´s Hospital|Liaoning Cancer Hospital & Institute|Guangzhou No.12 People´s Hospital|Second Xiangya Hospital of Central South University | SCLC, Limited Stage | 2024-05-22 | PHASE2 |
| NCT06692491 | Peking University Shenzhen Hospital | Rare Tumour | 2025-01-01 | PHASE2 |
| NCT07134101 | The First Affiliated Hospital with Nanjing Medical University | Colorectal Cancer (Diagnosis) | 2025-09-01 | PHASE2 |
| NCT06455072 | Fujian Cancer Hospital|Zhangzhou Municipal Hospital of Fujian Province | Cervical Cancer | 2023-02-01 | PHASE2 |
| NCT06850103 | First Affiliated Hospital of Zhejiang University|Ningbo No.2 Hospital|Ningbo Medical Center Lihuili Hospital|Second Affiliated Hospital of Wenzhou Medical University|Ningbo No. 1 Hospital|Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University|The Affiliated People´s Hospital of Ningbo University | Colorectal Carcinoma|Oligometastases|pMMR|MSS|iTNT | 2025-04-22 | PHASE2 |
| NCT07231445 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Small Cell Lung Cancer | 2026-04-21 | PHASE1 |
| NCT06531291 | RenJi Hospital | ESCC|Biliary Tract Cancer|Gastric Cancer|Pancreas Cancer | 2024-08-10 | PHASE2 |
| NCT06576921 | Xijing Hospital|Tang-Du Hospital|Hebei Medical University Fourth Hospital|Tianjin Medical University Cancer Institute and Hospital | Stomach Neoplasms|Immune Checkpoint Inhibitors | 2024-11-15 | PHASE2 |
| NCT06439550 | The First Affiliated Hospital of Zhengzhou University | HER2-positive Gastric Cancer | 2024-07-15 | PHASE2 |
| NCT05765825 | Sichuan University | Extensive-stage Small-cell Lung Cancer | 2023-03-07 | PHASE2 |
| NCT07336953 | West China Hospital | PDAC - Pancreatic Ductal Adenocarcinoma | 2026-02 | PHASE3 |
| NCT06422858 | Zhejiang Cancer Hospital | Locally Advanced Inoperable Esophageal Squamous Cell Carcinoma | 2024-05-20 | PHASE2 |
| NCT05831891 | RenJi Hospital|Shanghai Zhongshan Hospital | Non-clear Renal Cell Carcinoma | 2023-05-01 | PHASE2 |
| NCT06302062 | Guangzhou FineImmune Biotechnology Co., LTD. | Advanced Solid Tumor|Tumor Associated Lymph Node T Cell|Immunotherapy | 2023-06-06 | PHASE1 |
| NCT05659251 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Esophageal Squamous Cell Carcinoma|Neoadjuvant Therapy | 2022-12-01 | PHASE2 |
| NCT07177443 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Locally Advanced Nasopharyngeal Carcinoma | 2025-09-25 | PHASE3 |
| NCT07403435 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Esophageal Squamous Cell Carcinoma (ESCC) | 2026-02-15 | PHASE2 |
| NCT07150949 | Fudan University | Locally Advanced Rectal Cancer|Neoadjuvant Therapy | 2025-08-28 | PHASE2 |
| NCT05775796 | Fudan University | Non-small Cell Lung Cancer|Stage II-IIIA|Immunotherapy|Neoadjuvant Therapy | 2023-03-15 | PHASE2 |
| NCT05872685 | Yu jiren | Adenocarcinoma of the Stomach|Adenocarcinoma of Esophagogastric Junction|Proficient Mismatch Repair | 2023-12-24 | PHASE2 |
| NCT06388135 | Yang Jianjun, PhD | Esophageal Squamous Cell Carcinoma | 2024-05-01 | PHASE4 |
| NCT07064876 | Xi Junjie | Early Lung Cancer | 2025-10 | PHASE2 |
| NCT06419673 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Cervical Cancer | 2024-05-01 | PHASE2 |
| NCT07155122 | Fujian Cancer Hospital | Small-Cell Carcinoma of the Esophageal | 2025-09-01 | PHASE2 |
| NCT06860529 | Henan Cancer Hospital | HR&addition;+HER2- Breast Cancer | 2025-04-15 | PHASE2 |
| NCT06497530 | Guangzhou Institute of Respiratory Disease | Extensive-Stage Small Cell Lung Cancer | 2024-08 | PHASE2 |
| NCT07543848 | Chongqing University Cancer Hospital | Rectal Neoplasms|Rectal Adenocarcinoma | 2026-05-01 | PHASE2 |
| NCT07283692 | RenJi Hospital | Triple Negative Breast Cancer | 2026-02 | PHASE2 |
| NCT07020247 | West China Hospital | Locally Advanced Rectal Cancer (LARC)|Immunotherapy|Radiotherapy|Total Neoadjuvant Therapy|Anal Function Preservation | 2024-11-19 | PHASE3 |
| NCT05873790 | The First Hospital of Jilin University | Lung Cancer | 2023-06-01 | |
| NCT05766800 | Shanghai Pulmonary Hospital, Shanghai, China | Locally Advanced|Non-small Cell Lung Cancer | 2023-03-14 | PHASE2 |
| NCT07347951 | First Affiliated Hospital of Wenzhou Medical University | Locally Advanced Rectal Cancer (LARC) | 2025-12-01 | PHASE2 |
| NCT06364046 | The Central Hospital of Lishui City | Carcinoma|Small Cell Lung Cancer | 2024-04-01 | NA |
| NCT07391826 | The First Affiliated Hospital with Nanjing Medical University | Stage III Gastric Cancer | 2026-02-15 | PHASE2 |
| NCT05444374 | Sichuan Cancer Hospital and Research Institute | Cervical Cancer | 2022-10-01 | PHASE2 |
| NCT07340489 | Tianjin Medical University Cancer Institute and Hospital | Cervical Cancer | 2025-12-03 | PHASE2 |
| NCT06334757 | Henan Cancer Hospital | Non-Squamous Non-Small Cell Lung Cancer | 2023-05-08 | PHASE2 |
| NCT07446465 | Ye Xu | Colorectal Cancer (Locally Advanced or Metastatic)|Colorectal Cancer Microsatellite Stable (MSS) | 2026-03-01 | PHASE4 |
| NCT06848699 | Shanghai Henlius Biotech | Solid Tumor Cancer|Non Small Cell Lung Cancer | 2025-02-25 | PHASE1|PHASE2 |
| NCT06580665 | Shanghai Chest Hospital|Shanghai Henlius Biotech Co., Ltd.|AccuTarget MediPharma (Shanghai) Co., Ltd | Non-small Cell Lung Cancer | 2024-09-01 | NA |
| NCT05732493 | Fudan University | Locally Advanced Colon Cancer | 2023-03-01 | PHASE2 |
| NCT05837052 | Zhejiang University | Unresectable Lung Non-Small Cell Carcinoma | 2023-05-15 | PHASE2 |
| NCT06521866 | Fudan University | Advanced Colorectal Carcinoma|Immunotherapy | 2025-03-01 | PHASE2 |
| NCT07398937 | Fudan University | Resectable Stage II-IIIa Squamous NSCLC | 2026-02-05 | PHASE2 |
| NCT05918419 | Peking Union Medical College Hospital | Gastroesophageal Junction Adenocarcinoma | 2023-02-01 | PHASE2 |
| NCT05882513 | Second Affiliated Hospital, School of Medicine, Zhejiang University | NSCLC|Neoadjuvant Therapy | 2023-05-16 | PHASE2 |
| NCT07466303 | Xijing Hospital | Breast Cancer|Serplulimab Combined With SHR-A1811 as Neoadjuvant Therapy for Triple-Negative Breast Cancer | 2026-03-25 | PHASE2 |
| NCT06601309 | Fujian Medical University Union Hospital | Esophageal Squamous Cell Carcinoma | 2024-07-11 | PHASE2 |
| NCT07457528 | Tianjin Medical University Cancer Institute and Hospital | Resectable Esophageal Squamous Cell Carcinoma | 2026-03-12 | PHASE2 |
| NCT04301739 | Shanghai Henlius Biotech | Triple Negative Breast Cancer | 2020-04-17 | PHASE3 |
| NCT03973112 | Shanghai Henlius Biotech | Hepatocellular Carcinoma | 2019-09-24 | PHASE2 |
| NCT06115642 | Shanghai Henlius Biotech | Advanced+Metastatic Malignant Solid Tumors | 2023-11-24 | PHASE1 |
| NCT04033354 | Shanghai Henlius Biotech | Squamous Non Small Cell Lung Cancer | 2019-08-14 | PHASE3 |
| NCT04465734 | Shanghai Henlius Biotech | Hepatocellular Carcinoma (HCC) | 2022-11-15 | PHASE3 |
| NCT05443646 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Limited Stage Small Cell Lung Cancer | 2022-09-23 | PHASE2 |
| NCT05354700 | Shanghai Henlius Biotech | Small-cell Lung Cancer | 2023-03-29 | PHASE2 |
| NCT06857279 | Shanghai Henlius Biotech | Carcinoma of Head and+or Neck | 2025-04-22 | PHASE2 |
| NCT03941574 | Shanghai Henlius Biotech | MSI-H Solid Malignant Tumor | 2019-07-15 | PHASE2 |
| NCT04139135 | Shanghai Henlius Biotech | Gastric Cancer | 2019-12-12 | PHASE3 |
| NCT03468751 | Henlix, Inc | Solid Tumor | 2018-02-14 | PHASE1 |
| NCT07113275 | Tao Zhang | Rectal Cancer|Total Neoadjuvant Therapy|Radiotherapy|Immunotherapy | 2026-02-11 | PHASE3 |
| NCT04806945 | Shanghai Henlius Biotech | Cervical Cancer | 2022-09-30 | PHASE3 |
| NCT05290220 | Shanghai Henlius Biotech | Advanced Hepatocellular Carcinoma | 2022-08-01 | PHASE2 |
| NCT03952403 | Shanghai Henlius Biotech | Carcinoma|Non-Small-Cell Lung | 2019-12-02 | PHASE3 |
| NCT07487519 | Shanghai Henlius Biotech | Breast Cancer (Triple Negative Breast Cancer (TNBC)) | 2026-04-25 | PHASE2 |
| NCT03958890 | Shanghai Henlius Biotech | Esophageal Squamous Cell Carcinoma | 2019-06-19 | PHASE3 |
| NCT05483530 | Shanghai Henlius Biotech | Advanced or Metastatic Solid Tumors | 2022-12-14 | PHASE1 |
| NCT04547166 | Shanghai Henlius Biotech | Metastatic Colorectal Cancer | 2021-03-10 | PHASE2|PHASE3 |
| NCT05442996 | Shanghai Henlius Biotech | Solid Tumor, Adult | 2023-01-06 | PHASE1 |
| NCT05584137 | Shanghai Henlius Biotech | Colorectal Cancer Metastatic | 2023-06-15 | PHASE2 |
| NCT05513573 | Shanghai Henlius Biotech | Nasopharyngeal Carcinoma by AJCC V8 Stage | 2022-12-14 | PHASE2 |
| NCT05353257 | Shanghai Henlius Biotech | Limited-Stage Small Cell Lung Cancer | 2022-05-17 | PHASE3 |
| NCT05311189 | Shanghai Zhongshan Hospital | HER2-positive Gastric Cancer | 2022-04-15 | PHASE2 |
| NCT06349980 | Shanghai Henlius Biotech | Carcinoma, Hepatocellular | 2024-08-05 | PHASE2 |
| NCT05239650 | Shanghai Henlius Biotech | CRC | 2022-07-15 | PHASE2 |
| NCT04063163 | Shanghai Henlius Biotech | Extensive Stage Small Cell Lung Cancer | 2019-09-12 | PHASE3 |
| NCT07507916 | Fudan University | ctDNA|Gastric Cancer|Gastroesophageal Junction (GEJ) Adenocarcinoma|Adjuvant Treatment | 2026-04-01 | PHASE2 |
| NCT04947826 | Shanghai Zhongshan Hospital|Shanghai Henlius Biotech | Hepatocellular Carcinoma With Major Portal Vein Thrombosis | 2021-08 | PHASE2 |
| NCT04297995 | Shanghai Henlius Biotech | Head and Neck Squamous Cell Carcinoma | 2020-07-29 | PHASE2 |
| NCT05400265 | Shanghai Henlius Biotech | Adult Solid Tumor | 2022-07-26 | PHASE1 |
| NCT03757936 | Shanghai Henlius Biotech | Solid Tumor | 2018-11-27 | PHASE1 |